drugset / Trial / NCT00645515

A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia

NCT00645515

Phase 3 Terminated 240 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. The primary purpose is to differentiate the effects of ziprasidone and risperidone on extrapyramidal side effects and the secondary purpose is to compare their tolerability and efficacy.

Timeline

Start
2003-06
Primary completion
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risperidone Other / unclassified 3 mg
Comparator Risperidone Other / unclassified 9 mg
Subject Ziprasidone Small molecule 40 mg
Subject Ziprasidone Small molecule 80 mg

Indications